2. Academic Validation
  3. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

  • J Hematol Oncol. 2015 Apr 23;8:41. doi: 10.1186/s13045-015-0137-1.
Kai Zhao 1,  Yuxin Zhou 2,  Chen Qiao 3,  Ting Ni 4,  Zhiyu Li 5,  Xiaotang Wang 6,  Qinglong Guo 7,  Na Lu 8,  Libin Wei 9
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. cpuzhaokai@163.com.
  • 2 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. zyxspain@hotmail.com.
  • 3 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. qiaochen1987@163.com.
  • 4 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. 1179720746@qq.com.
  • 5 Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. zhiyuli@cpu.edu.cn.
  • 6 Department of Chemistry and Biochemistry, Florida International University, Miami, FL, 33199, USA. wangx@fiu.edu.
  • 7 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. anticancer_drug@163.com.
  • 8 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. luna555@163.com.
  • 9 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, The People's Republic of China. wlbiws_1986@aliyun.com.
PMID: 25902914 DOI: 10.1186/s13045-015-0137-1
Abstract

Introduction: p53 plays important roles in regulating the metabolic reprogramming of Cancer, such as aerobic glycolysis. Oroxylin A is a natural active flavonoid with strong Anticancer effects both in vitro and in vivo.

Methods: wt-p53 (MCF-7 and HCT116 cells) Cancer cells and p53-null H1299 Cancer cells were used. The glucose uptake and lactate production were analyzed using Lactic Acid production Detection kit and the Amplex Red Glucose Assay Kit. Then, the protein levels and RNA levels of p53, mouse double minute 2 (MDM2), and p53-targeted glycolytic Enzymes were quantified using Western blotting and quantitative polymerase chain reaction (PCR), respectively. Immunoprecipitation were performed to assess the binding between p53, MDM2, and sirtuin-3 (SIRT3), and the deacetylation of Phosphatase and tensin homolog (PTEN). Reporter assays were performed to assess the transcriptional activity of PTEN. In vivo, effects of oroxylin A was investigated in nude mice xenograft tumor-inoculated MCF-7 or HCT116 cells.

Results: Here, we analyzed the underlying mechanisms that oroxylin A regulated p53 level and glycolytic metabolism in wt-p53 Cancer cells, and found that oroxylin A inhibited glycolysis through upregulating p53 level. Oroxylin A did not directly affect the transcription of wt-p53, but suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 Cancer cells. In further studies, we found that oroxylin A induced a reduction in MDM2 transcription by promoting the lipid Phosphatase activity of Phosphatase and tensin homolog, which was upregulated via sirtuin3-mediated deacetylation. In vivo, oroxylin A inhibited the tumor growth of nude mice-inoculated MCF-7 or HCT116 cells. The expression of MDM2 protein in tumor tissue was downregulated by oroxylin A as well.

Conclusions: These results provide a p53-independent mechanism of MDM2 transcription and reveal the potential of oroxylin A on glycolytic regulation in both wt-p53 and mut-p53 Cancer cells. The studies have important implications for the investigation on Anticancer effects of oroxylin A, and provide the academic basis for the clinical trial of oroxylin A in Cancer patients.

Figures
Products